生華生物科技股份有限公司
生華生物科技股份有限公司（Senhwa Biosciences, Inc.）從事新藥及標靶藥物之開發。研發管線包括 CX-5461（用於血液與實體腫瘤）、CX-4945（用於膽管癌及基底細胞癌）、及針對新冠肺炎住院患者的治療研究。公司涉及 AI 驅動藥物開發模型。公司成立於 2012 年，總部位於台灣新北。
該股 RSI(6) 為 51.4，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日均線，跌破60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=56.2）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -24 | 0 | 0 | -24 |
| 09-23 | +54 | 0 | 0 | +54 |
| 09-22 | -16 | 0 | 0 | -16 |
| 09-21 | +14 | 0 | 0 | +14 |
| 09-18 | -26 | 0 | 0 | -26 |
| 09-17 | +73 | 0 | 0 | +73 |
| 09-16 | +11 | 0 | 0 | +11 |
| 09-15 | +10 | 0 | +2 | +10 |
| 09-14 | -43 | 0 | 0 | -43 |
| 09-11 | +34 | 0 | 0 | +34 |
| 09-10 | -21 | 0 | +2 | -21 |
| 09-09 | +37 | 0 | 0 | +37 |
| 09-08 | +18 | 0 | 0 | +18 |
| 09-07 | +159 | 0 | +2 | +159 |
| 09-04 | +77 | 0 | +2 | +77 |
| 09-03 | -59 | 0 | +4 | -59 |
| 09-02 | -5 | 0 | 0 | -6 |
| 09-01 | +11 | 0 | 0 | +11 |
| 08-31 | -60 | 0 | +10 | -115 |
| 08-28 | +125 | 0 | +4 | +75 |
| 08-27 | +100 | 0 | +10 | +50 |
| 08-26 | +53 | 0 | +10 | +3 |
| 08-25 | +231 | 0 | +2 | +181 |
| 08-24 | +119 | 0 | +4 | +59 |
| 08-21 | +523 | 0 | +20 | +473 |
| 08-20 | +42 | 0 | 0 | +42 |
| 08-19 | -6 | 0 | 0 | -6 |
| 08-18 | -12 | 0 | 0 | -12 |
| 08-17 | +30 | 0 | 0 | +30 |
| 08-14 | +11 | 0 | 0 | +11 |
| 08-13 | -5 | 0 | 0 | -5 |
| 08-12 | +131 | 0 | 0 | +131 |
| 08-11 | +99 | 0 | 0 | +99 |
| 08-10 | +162 | 0 | +2 | +162 |
| 08-07 | +10 | 0 | +12 | +10 |
| 08-06 | -18 | 0 | +8 | -19 |
| 08-05 | -57 | 0 | +8 | -56 |
| 08-04 | +130 | 0 | 0 | +130 |
| 08-03 | +47 | 0 | +2 | +47 |
| 07-31 | +15 | 0 | 0 | +15 |
| 07-30 | +121 | 0 | +2 | +121 |
| 07-29 | +235 | 0 | +2 | +235 |
| 07-28 | +123 | 0 | +4 | +123 |
| 07-27 | +50 | 0 | +2 | +50 |
| 07-24 | -25 | 0 | +2 | -25 |
| 07-23 | -7 | 0 | 0 | -8 |
| 07-22 | -49 | 0 | +2 | -49 |
| 07-21 | +40 | 0 | 0 | +40 |
| 07-20 | +1 | 0 | 0 | +1 |
| 07-17 | -2 | 0 | 0 | -2 |
| 07-16 | +55 | 0 | 0 | +55 |
| 07-15 | +55 | 0 | 0 | +55 |
| 07-14 | +25 | 0 | 0 | +25 |
| 07-13 | +32 | 0 | 0 | +32 |
| 07-09 | -24 | 0 | +2 | -24 |
| 07-08 | -32 | 0 | 0 | -32 |
| 07-07 | +62 | 0 | +1 | +62 |
| 07-06 | +43 | 0 | 0 | +43 |
| 07-03 | +41 | 0 | 0 | +41 |
| 07-02 | +20 | 0 | 0 | +20 |
| 07-01 | +24 | 0 | 0 | +24 |
| 06-30 | +89 | 0 | +12 | +89 |
| 06-29 | +27 | 0 | 0 | +27 |
| 06-26 | +2 | 0 | +2 | +2 |
| 06-25 | +46 | 0 | +2 | +46 |
| 06-24 | +31 | 0 | 0 | +31 |
| 06-23 | +19 | 0 | +2 | +19 |
| 06-22 | -22 | 0 | +2 | -22 |
| 06-18 | -14 | 0 | 0 | -14 |
| 06-17 | +40 | 0 | 0 | +40 |
| 06-16 | -1 | 0 | 0 | -1 |
| 06-15 | +11 | 0 | 0 | +11 |
| 06-12 | +41 | 0 | 0 | +41 |
| 06-11 | +46 | 0 | +2 | +47 |
| 06-10 | -21 | 0 | +6 | -21 |
| 06-09 | +50 | 0 | 0 | +50 |
| 06-08 | -22 | 0 | +10 | -22 |
| 06-05 | +48 | 0 | 0 | +48 |
| 06-04 | +18 | 0 | 0 | +18 |
| 06-03 | +3 | 0 | +4 | +4 |
| 06-02 | 0 | 0 | +2 | 0 |
| 06-01 | +144 | 0 | 0 | +143 |
| 05-29 | +50 | 0 | +2 | +50 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 8 萬 | 0.0% | -3.6% |
| 2026/03 | 8 萬 | 0.0% | -3.6% |
| 2026/02 | 8 萬 | 0.0% | -4.8% |
| 2026/01 | 8 萬 | 0.0% | -3.6% |
| 2025/12 | 8 萬 | 0.0% | -4.8% |
| 2025/11 | 8 萬 | 0.0% | -3.6% |
| 2025/10 | 8 萬 | -51.2% | -3.6% |
| 2025/09 | 16 萬 | +97.6% | +95.2% |
| 2025/08 | 8 萬 | 0.0% | 0.0% |
| 2025/07 | 8 萬 | -1.2% | 0.0% |
| 2025/06 | 8 萬 | +1.2% | 0.0% |
| 2025/05 | 8 萬 | - | 0.0% |